Latest Breaking News On - Compas scientific founder - Page 1 : comparemela.com

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 in patients with advanced biliary tract cancer . Consistent with prior guidance, top.

United statesVered bisker leibThomas schuetzDanna giffordCarl gordonCompass therapeutics incExchange commissionGlobenewswire incDevelopment pipeline updatesCompass presidentCompass chief executive officerCompas scientific founderChief executive officerVice chairPipeline updatesAdaptive simon two stage